Despite largely ubiquitous VHL inactivation and 3p loss in ccRCC tumors, there is a wide variation in clinical outcomes, which brings into question the role of subclonal and passenger mutations in tumor progression and drug resistance [5,6]. Here, VHL is linked to nonpapillary renal cell carcinoma.